<DOC>
	<DOCNO>NCT00753480</DOCNO>
	<brief_summary>This Phase I , multicenter , open-label , dose-escalation study single-agent D4064A administer IV infusion patient recurrent persistent epithelial ovarian cancer ( EOC ) , primary peritoneal cancer ( PPC ) , fallopian tube cancer ( FTC ) previously receive platinum-containing regimen . The study enroll 56 patient six investigative site United States .</brief_summary>
	<brief_title>A Study D4064A Administered Patients With Recurrent Persistent Epithelial Ovarian , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>ECOG performance status 0 1 Advanced , histologically document epithelial ovarian , primary peritoneal , fallopian tube cancer progress relapse within 12 month treatment platinumcontaining chemotherapy regimen , standard therapy exist History receive five few prior chemotherapycontaining regimen EOC , PPC , FTC ( include primary therapy ) Prior treatment chemotherapy experimental anticancer agent within 4 week prior Day 1 Prior treatment oregovomab ( OvaRex ( R ) ) abagovomab History clinical evidence central nervous system brain metastasis Grade â‰¥ 2 peripheral neuropathy History severe allergic anaphylactic reaction human , humanize , chimeric , murine monoclonal antibody History clinically symptomatic liver disease , include viral hepatitis , history current alcoholism , cirrhosis Untreated persistent/recurrent malignancy ( EOC , PPC , FTC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>EOC</keyword>
	<keyword>PPC</keyword>
	<keyword>FTC</keyword>
</DOC>